Green Cross Holdings has bought the entire 22.1% stake in GC Wellbeing from GC Nokshimja for 50.5 billion won, consolidating ownership of a key subsidiary in the Green Cross Group. The transaction, disclosed on July 1 via the Financial Supervisory Service's electronic system, signals a potential shift in the group's co-management structure between uncle and nephew. Observers see this as a step toward restructuring amid growing assets and succession pressures.
Strategic Shift in Ownership
Green Cross Holdings, the group's holding company, paid cash for the 3,920,250 common shares GC Nokshimja held in GC Wellbeing. This acquisition gives Holdings complete control over the subsidiary, which the company described as a move to enhance corporate value and refine its business portfolio. GC Nokshimja, in turn, aims to strengthen its financial position and fund investments in its core blood products business.
GC Wellbeing's Rising Profile
GC Wellbeing stands out within the group for its diverse portfolio in placenta injections, vitamin injections, and health functional foods. The subsidiary recently entered aesthetic medicine by acquiring Innibio, a botulinum toxin firm, for 40 billion won last year. Last month, it launched Giselle Rebonne, an extracellular matrix skin booster positioned as a next-generation aesthetic product. These expansions highlight GC Wellbeing's role in driving new revenue streams for the group.
Implications for Group Governance
The deal occurs against a backdrop of joint management by Chairman Huh Il-sub of Green Cross Holdings and the sons of the late former chairman Huh Young-sub: Huh Eun-chul at GC Nokshimja and Huh Yong-jun at Holdings. Chairman Huh holds the largest stake at 12.28% in Holdings, while the nephews own 2.68% and 2.91% respectively. With group assets nearing 5 trillion won, the Fair Trade Commission may soon designate it a large business group, prompting scrutiny of its structure.
Succession and Restructuring Pressures
Analysts interpret the transaction as groundwork for separating affiliates, allowing each to focus on core operations. A company official stated the move establishes foundations for specialized growth: GC Nokshimja on blood products and Holdings on opportunities linked to GC Wellbeing. At age 70, Chairman Huh faces calls for a clear succession plan, as unresolved family dynamics could lead to disputes similar to those in other pharmaceutical families.
